Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186174 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLFKBP1A | |
| SCHEMBL185522 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLFKBP1A | |
| Ammonia Solution, Strong SCHEMBL28111366 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2HSD17B10RECQLFKBP1A | |
| SCHEMBL18555204 | 0.91 | HSD17B10 (0.51) | SMN1; SMN2USP2HSD17B10RECQLKLK7 | |
| SCHEMBL31148667 | 0.91 | HSD17B10 (0.51) | SMN1; SMN2USP2HSD17B10RECQLKLK7 | |
| SCHEMBL18555206 | 0.91 | HSD17B10 (0.51) | SMN1; SMN2USP2HSD17B10RECQLKLK7 | |
| SCHEMBL13804186 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLCA12 | |
| SCHEMBL15116754 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2HSD17B10RECQLCA12 | |
| SCHEMBL3511572 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2HSD17B10RECQLCA12 | |
| SCHEMBL16359137 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2HSD17B10RECQLCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 715 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | claimed |
| CN-111533708-B | Preparation method of chiral N-tert-butoxycarbonylmorpholine-3-carboxylic acid | 上海馨远医药科技有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-111533708-A | Preparation method of chiral N-tert-butoxycarbonylmorpholine-3-carboxylic acid | 上海馨远医药科技有限公司 | 2020-08-14 | — | — | CN | claimed |
| EP-1581525-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | claimed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | claimed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4463455-B1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LTD (IN) | 2026-04-29 | — | — | EP | disclosed |
| EP-4558507-B1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | disclosed |
| CN-1252799-A | N-heterocyclic derivatives as NOS inhibitor | BERLEX LAB (US) | 2000-05-10 | — | — | CN | disclosed |
| EP-0968206-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998037079-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SMN1; SMN2 2568/4885USP2 1630/4885HSD17B10 334/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | SMN1; SMN2 1555/4885USP2 4448/4885HSD17B10 1075/4885 |
| US-20040106607-A1 | New compounds | MTX1, MLX, TPX2 | SMN1; SMN2 2508/4885USP2 4226/4885HSD17B10 3279/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SMN1; SMN2 2568/4885USP2 1630/4885HSD17B10 334/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | SMN1; SMN2 3226/4885USP2 4447/4885HSD17B10 1259/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | SMN1; SMN2 881/4885USP2 3255/4885HSD17B10 1168/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | SMN1; SMN2 2568/4885USP2 1630/4885HSD17B10 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.